Clinical Trials Browser

Phase 1/2 × Anemia, Aplastic × 30 days × Clear all

NCT06303193 2026-06-05

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Phase 1/2 Recruiting

Classical hematologyMyeloid

Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Bone Marrow Diseases, Myelodysplastic Syndromes, Myeloproliferative Disorders